# Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)

> **NCT02194595** · PHASE3 · COMPLETED · sponsor: **Mount Sinai Hospital, Canada** · enrollment: 105 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Basal insulin and exenatide
- **DRUG:** Basal insulin only
- **DRUG:** Basal insulin and bolus insulin

## Key facts

- **NCT ID:** NCT02194595
- **Lead sponsor:** Mount Sinai Hospital, Canada
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2021-12
- **Final completion:** 2022-02
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2022-04-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02194595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02194595, "Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02194595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*